This is a dose-escalation study of dasatinib and bevacizumab (Group 1) followed by a randomized study (Group 2). The dose-escalation phase of the study has been completed. Group 2 is now enrolling.
An excellent, easy-to-understand, summary of the 10th International Kidney Cancer Symposium, as reported by Joyce Wilcox Graff, Director of Wellness, VHL Family Alliance.
Viagra may provide more than a wake-up to a man's sex life it may help the body's immune system fight cancer, a new study involving mice suggests.
Over the last year the recurrence rate has further declined leading the advisers to conclude that the trial has matured such that the final analysis can be conducted now instead of after 512 events as originally planned.
The following Drug Information Sheets (PDFs) will help you to learn more about these, including common side effects that users may experience.
The Genomics Initiative will use the latest high-tech gene sequencing machines to address specific research questions that until now were impossible to answer.
...during its November meeting. CT Medicaids P&T decision requiring doctors to go through a prior authorization process for some agents, but not others, creates a two tiered system that is not grounded in the evidence that oncologists utilize to make their treatment decisions.
The removal of rare tumor cells circulating in the blood might be possible with the use of biomolecules bound to dendrimers...
Medicare says it will continue to cover Avastin for breast cancer treatment, even if the FDA withdraws it for such use.
...the committee will discuss new drug application (NDA) 202324, with the proposed trade name INLYTA (axitinib) tablets, application submitted by Pfizer Inc. The proposed indication (use) for this product is for the treatment of patients with advanced renal cell carcinoma (RCC, kidney cancer).